Mereo BioPharma Group Plc (MREO) is a biopharmaceutical company specialized in acquiring, developing, and commercializing innovative therapeutics to serve patients with rare diseases. The London-based company was founded in 2015 and has since made a name for itself for pioneering novel therapies for rare, life-limiting conditions that have inadequate treatment options.
Mereo's strategy involves acquiring product candidates that have already undergone some clinical development, thus limiting drug discovery risks. This approach enables it to focus on the decisive stages of drug development and commercialization. Notably, the company’s modern drug development program leverages technology to streamline operations and fast-track the approval process while maintaining a patient-centric approach.
Mereo BioPharma's therapeutic area covers a broad range of conditions encompassing endocrinology, oncology, and rare genetic diseases. The company’s robust pipeline comprises of multiple product candidates, some of which are in advanced clinical stages. Key programs include Setrusumab for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Alvelestat for Alpha-1 Antitrypsin Deficiency.
Moreover, the company is piloting the development of Etigilimab, an immune-modulating therapy for cancer treatment. By addressing areas of high unmet medical need, Mereo aims to alleviate the suffering of patients living with these rare conditions while creating value for its shareholders.
Collaborations and partnerships hold a central place in Mereo’s business model. They engage with larger pharmaceutical businesses to leverage their strengths in research, commercialization, and global market access. Their partnership with Oncologie, for instance, enabled them to further develop Navicixizumab, a promising drug candidate for advanced ovarian cancer.
In the industry, the company enjoys a reputation for integrity, innovation, and commitment to corporate responsibility. Mereo BioPharma Group Plc is publicly traded on the Nasdaq Global Market and the AIM Market of the London Stock Exchange under the ticker symbol “MREO”.
The journey of Mereo BioPharma Group Plc continually emphasizes its dedication to making a real difference in rare disease treatment. By focusing on areas of high unmet need, the company is developing a sustainable future where all patients can look forward to a lifetime of possibilities. Through its focused strategy and patient-centric approach, the company is not just creating medicines, but shaping better lives for patients.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
JPMorgan Chase & Co. has reiterated its "underweight" rating for Mereo BioPharma Group (MREO), despite "buy" ratings from other firms like Needham and BTIG. The stock holds an overall "Hold" rating from analysts with an average price target of $3.25. Mereo BioPharma Group reported quarterly earnings of -$0.01 per share, meeting analyst estimates, and institutional investors own 62.83% of the company's stock.
JPMorgan has downgraded Mereo BioPharma (MREO) from Neutral to Underweight. This change in rating reflects a less optimistic outlook on the biopharmaceutical company's stock by the financial institution. The article also provides a company profile, detailing Mereo BioPharma's focus on rare diseases and its pipeline of late-stage clinical product candidates.
Mereo BioPharma Group plc reported a narrower loss for the second quarter of 2026, with a loss per share of $0.01 compared to $0.02 in the prior year, despite recording no revenue. The company achieved a net loss of $7.0M, attributed to substantial reductions in operating expenses. Wall Street analysts maintain a generally positive outlook with 5 buy and 4 hold ratings.
Zydus's Sentynl and Mereo BioPharma have partnered to advance alvelestat, a rare disease drug. This collaboration provides a crucial boost for alvelestat's development. The article also mentions updates on other candidates, setrusumab and vantictumab, with the latter progressing to Phase II.
Mereo BioPharma Group (MREO) reported a narrower net loss for Q2 2026, posting a loss per share of $0.01 and a net loss of $7.0M, an improvement from the previous year. Despite having no revenue, the biopharmaceutical company reduced operating expenses, focusing on advancing its rare disease therapeutic pipeline. Analysts maintain a positive outlook on the stock, with 5 buy and 4 hold ratings.